COPD? ASTHMA? EMPHYSEMA?

It could be Alpha-1

If you are one of the millions suffering with COPD, emphysema, or asthma, it's important to find out for sure if you have the right diagnosis.

You could be one of the estimated 60,000-100,0001,2 people who has Alpha-1 Antitrypsin Deficiency.

ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]

ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.

The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.

In a clinical trial, the most common adverse events deemed related to ARALAST NP included headache and musculoskeletal discomfort. No serious adverse reactions or deaths were reported in the study. In a clinical trial of ARALAST, the most common adverse events were headache and somnolence.

Please refer to the Aralast NP Important Risk Information link above for more detailed risk information and the ARALAST NP Prescribing Information link for full prescribing details.

What's the difference?

Alpha-1 is often misdiagnosed.3 Why the confusion? The symptoms of Alpha-1 are the same as COPD, asthma, and emphysema.3

But Alpha-1 is different – it's inherited. People with Alpha-1 have low levels or are lacking a lung-protecting protein called Alpha-1 Antitrypsin (AAT). Without AAT, people are at higher risk for developing lung diseases such as emphysema or COPD .3

Finding out whether Alpha-1 is the cause of your lung disease is important. An accurate diagnosis is the first step in making the best therapy and lifestyle decisions for you and your family.

ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]

ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.

The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.

In a clinical trial, the most common adverse events deemed related to ARALAST NP included headache and musculoskeletal discomfort. No serious adverse reactions or deaths were reported in the study. In a clinical trial of ARALAST, the most common adverse events were headache and somnolence.

Please refer to the Aralast NP Important Risk Information link above for more detailed risk information and the ARALAST NP Prescribing Information link for full prescribing details.

Am I at risk?

If you have one or more of these symptoms or risk factors, you could have Alpha-1.4

Risk Factors:

  • Early onset of emphysema (age 45 years or less)
  • COPD – emphysema, chronic bronchitis or bronchiectasis
  • Family history of any of the following: emphysema/COPD, liver disease, or panniculitis
  • Asthma with minimal response to medication, inhalers
  • Liver disease with unknown cause

Symptoms:

  • Shortness of breath with routine activity
  • Cough with or without mucus
  • Wheezing

ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]

ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.

The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.

In a clinical trial, the most common adverse events deemed related to ARALAST NP included headache and musculoskeletal discomfort. No serious adverse reactions or deaths were reported in the study. In a clinical trial of ARALAST, the most common adverse events were headache and somnolence.

Please refer to the Aralast NP Important Risk Information link above for more detailed risk information and the ARALAST NP Prescribing Information link for full prescribing details.

Find out for sure – get tested.

Testing is simple.

Order a complimentary test kit and take it to your doctor. The test kit contains everything you and your doctor need to find out for sure.

Your doctor will take a simple finger-stick blood sample. Within two weeks of submitting your sample in the pre-addressed and postage paid envelope, your doctor will have an answer.

Request a complimentary AlphaTest® Kit.

Baxter is pleased to send you a complimentary test kit to take to your doctor. Just fill out the online test kit request form or call 1-866-272-5278.

ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]

ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.

The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.

In a clinical trial, the most common adverse events deemed related to ARALAST NP included headache and musculoskeletal discomfort. No serious adverse reactions or deaths were reported in the study. In a clinical trial of ARALAST, the most common adverse events were headache and somnolence.

Please refer to the Aralast NP Important Risk Information link above for more detailed risk information and the ARALAST NP Prescribing Information link for full prescribing details.

References

  1. American Lung Association. COPD Fact Sheet. Available at http://www.lungusa.org/lung-disease/copd/resources/facts-figures/COPD-Fact-Sheet.html.  Accessed April 7, 2010.
  2. de Serres FJ, Blanco I, Fernández-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand; Australia, Canada, New Zealand and the United States of America. Clin Genet. 2003; 64; 382-397.
  3. The American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with AAT deficiency. Am J Respir Crit Care Med. 2003;168:818-900.
  4. Adapted from the American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with AAT deficiency. Am J Respir Crit Care Med. 2003;168:818-900.